Castle Biosciences
- Market cap
- 1.01B
- P/E (TTM)i
- -51.56
- P/Bi
- 2.14
- EPSi
- -0.83
- Div yieldi
- 0.00%
- 52W posi
- 58%
Anonymous reader poll. Unscientific, not investment advice.
About Castle Biosciences
Castle Biosciences, Inc. is a molecular diagnostics company, which offers innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
- Founded
- 2007
- CEO
- Mr. Derek J. Maetzold
- Employees
- 883
- Headquarters
- Friendswood, Texas, United States of America
- Fiscal year end
- 12-31
- Website
- castlebiosciences.com
Company profile
- Exchange
- US
- Symbol
- CSTL
- Market-cap rank
- #3242
- Listing date
- 2019-07-25
- Market cap
- 1.01B
- Float cap
- 896.04M
- Shares out
- 30.55M
- Float shares
- 27.15M
Sectors & themes
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.